Thursday, May 08, 2014 9:54:32 AM
I actually just see no a priori reason to think that the ligand binding chemistry of the Flucide that has worked so well in animal models would suddenly stop working in human systems and within a chemically similar mamalian circulatory system.
I actually just see no a priori reason to think that there would suddenly be significant Toxic effects to human cells and organ systems, when no such effects have been observed in biologically similar mamalian cells and organ systems.
BUT - and this is the big but - a possibility does exist that there could be toxic effects at proposed clinical levels of Flucide for humans. AND - there is a possibility that there is some overlooked factor in human biology that might decrease or eliminate effective anti-flu activity for Flucide.
THAT IS WHY they need to do the testing. PERIOD.
THAT IS ALSO WHY - in order to silence the most vocal of current critics - they need to get those studies done, those data collected, and any analyses completed.
It's not 'Hope' that the product works as it appears it should work.
It's an expectation that the mound of animal testing data to date has some predictive value as to what to expect. It's an expectation that chemistry and ligand binding are predictable and stable.
So - to call it "Hope" is to mischaracterize the thinking of (at least) this particular long holder.
“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy
Recent NNVC News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 09:30:36 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/15/2024 08:44:44 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/27/2024 08:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
FEATURED Key Metals Surge, Unlocking New Opportunities for Savvy Mining Investors • Nov 19, 2024 8:45 AM
FEATURED Greenlane Signs New U.S. Distribution Agreement with Veriteque USA, Manufacturer of the SwabTek™ and Verifique™ Brand of Field Test Kits • Nov 19, 2024 8:34 AM
FEATURED Are we about to see a comeback? Steakholder Foods Charges Forward with New Commitments from Multiple International Players as it Transitions to Revenue Generation • Nov 18, 2024 11:56 AM
Geo-Political Tensions and Trump's Increasing Military Budgets Could Boost Demand for Actelis' Cyber Hardened Networking Tech ($ASNS) • ASNS • Nov 19, 2024 10:24 AM
CBD Life Sciences Inc. (CBDL) Closes on LOI for Potential $8 Million Revenue Cannabis Dispensary • CBDL • Nov 19, 2024 8:00 AM
North Bay Resources Announces Production of Gold Concentrate and Refinery Shipment at Bishop Gold Mill, California • NBRI • Nov 18, 2024 9:00 AM